CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 3rd Annual series of webcast “RNAi Roundtables” this summer and early fall. The 2016 series will consist of presentations from Alnylam scientists, clinical collaborators, and patients or patient advocates, who will review recent progress in many of the Company’s development-stage pipeline programs.
